Autophagy and mitophagy are important cellular processes that are responsible for breaking down cellular contents, preserving energy and safeguarding against accumulation of damaged and aggregated biomolecules. This graphic review gives a broad summary of autophagy and discusses examples where autophagy is important in controlling protein degradation. In addition we highlight how autophagy and mitophagy are involved in the cellular responses to reactive species and mitochondrial dysfunction. The key signaling pathways for mitophagy are described in the context of bioenergetic dysfunction.
Introduction
Cellular damage occurs in response to genetic perturbations, nutrient deprivation, aging, and environmental toxins. The task of managing general and specific cellular damage is largely under the control of the highly regulated process called autophagy. The term autophagy is used to describe lysosomal-mediated degradation of intracellular contents, which can be divided into 3 basic mechanisms: (1) chaperone-mediated autophagy, (2) microautophagy, and (3) macroautophagy (Fig. 1) . Chaperone-mediated autophagy, initiated by chaperone Hsc70, recognizes one protein at a time, and Hsc70 carries the protein to the lysosomes via binding to the lysosomal associated membrane protein (LAMP2A). The proteins recognized by Hsc70 contain the KFERQ consensus sequence [1] . Whether additional chaperones and lysosomal receptors participate in chaperone-mediated autophagy is unknown. Microautophagy is achieved by invagination of lysosomal membranes. Lipid, protein or organelles can be degraded through this pathway. Recent studies have shown that proteins containing the KFERQ consensus sequence may also be recruited to the lysosomes via phosphatidylserine, and degraded by microautophagy [1] . Whether lipid, organelles and other proteins are marked by specific modifications to be recognized by the lysosomes is highly likely but the majority of these have yet to be defined.
Macroautophagy is the most extensively studied autophagy process [2] . It was first described using electron microscopy as unique morphological structures with double membranes encircling amorphous or partially degraded materials including mitochondria and endoplasmic reticulum. Early studies noted that these structures are enriched in response to glucagon and starvation in the liver [3] . During the past 2 decades, more than 35 genes have been identified in yeast and most of the corresponding Contents lists available at SciVerse ScienceDirect journal homepage: www.elsevier.com/locate/redox mammalian homologs have been identified [4] . The mTOR pathway plays a major role in sensing free amino acids, cellular bioenergetic deficits, hypoxia and DNA damage, and thereby regulate macroautophagy [5] . The sensing of free amino acids by mTOR seems to be dependent on localization of the mTOR complex to the lysosomes [5] .
One major function of macroautophagy is the control of accumulation of over-produced, long-lived or damaged proteins. Deficiencies Autophagic clearance of aggregation-prone proteins. Due to either genetic predisposition, aging or environmental perturbations, specific proteins may become unfolded, abnormally modified, or mis-targeted. If accumulated, these protein species may cause further cellular damage and induce cell death. This is particularly important in postmitotic cells which cannot divide and so dilute out these toxic species. Protein aggregates or inclusions accumulate in neurodegenerative diseases, including Alexander disease, multiple system atrophy, Alzheimer's, Parkinson's and Huntington's diseases. One such protein is a-synuclein, which may exist in 3 different forms: (1) synaptic vesicleassociated form that may be involved in synaptic neurotransmitter release, (2) cytosolic form which may target to the mitochondria and is able to inhibit mitochondrial complex I activity, and (3) a-synuclein modified by reactive species or phosphorylation. Plasma membrane associated protein can be degraded by the endosomes. Cytosolic unmodified a-synuclein can be degraded by both the proteasome pathway and the lysosomal-mediated autophagy pathway. Wildtype a-synuclein can also be recognized by chaperone protein Hsc70 and transported to the lysosomes for degradation through the chaperone-mediated autophagy. However, a-synuclein modified at serine 129 which accumulates in Parkinson's disease Lewy Bodies, and mutated a-synuclein as appears in familial Parkinson's disease, cannot be degraded through the chaperone-mediated autophagy. They further contribute to cytotoxicity by inhibition of chaperone-mediated autophagy preventing removal of a-synuclein and other protein targets. (Fig. 2) . However, a-synuclein that is phosphorylated at serine 129 as appears in Lewy Bodies in
Parkinson's disease, and a-synuclein that is mutated in familial
Parkinson's disease cannot be degraded by chaperone-mediated autophagy [10] , and is thus presumably highly sensitive to blockade of macroautophagy. The proteases within the lysosome can be limiting in the degradation of aggregated proteins. We and others have shown that lysosomal cathepsin D deficient mice, sheep and patients exhibit a-synuclein accumulation, indicating that autophagy is important for a-synuclein turnover [11, 12] . Additional examples of autophagy playing important roles in decrease protein accumulation include the involvement of cathepsin B in amyloid beta accumulation [13] , and the involvement of autophagy protein Atg5 and Atg7 in ubiquitinated protein accumulation [14, 15] . Cellular damage can arise both from accumulation of toxic species of proteins that may be detrimental to redox signaling or even directly inhibitory to mitochondrial function, and as a consequence of mitochondrial dysfunction. Indeed, mitochondria are major hub in the cell integrating energy demand, reactive species and apoptosis signaling. Mitochondrial dysfunction and accumulation of oxidative damage contribute to pathogenesis of a variety of diseases, including neurodegenerative diseases, liver steatosis, lung and cardiovascular diseases, and cancer [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] (Fig. 3) . Specific examples include decreased complex I activity, increased mitochondrial and nuclear DNA damage, and decreased reduced glutathione [32] [33] [34] [35] [36] [37] . Of particular interest to redox biology, oxidative stress can either be a signal to activate autophagy, or exert damage to the autophagy machinery to inhibit autophagy. For example, oxidative stress may increase DNA damage, activate p53 and AMPK which in turn inhibits mTOR and activates autophagy [38] . On the other hand, Atg4 is activated in reduced conditions, and inactivated in response to oxidative stress [39] . Reciprocally, autophagy may decrease cellular oxidative stress by clearance of reactive species generating organelles, reactive species damaged proteins, or alternatively, decrease specific antioxidants [40] . A similar relationship between mitochondrial activities and autophagy also exists. Mitochondria-deficient cells or cells treated with oligomycin or antimycin A, exhibit attenuated autophagic gene induction and autophagic flux in response to starvation [41] . Furthermore, mitochondrial contribution to activation of macroautophagy may include generation of reactive species [42] , providing membranes for autophagosomal formation [43] , or providing a platform for membrane-associated complexes to engage the autophagy process [44] .
Autophagic removal of mitochondria is important for mitochondrial quality control. Poor quality mitochondria may enhance cellular oxidative stress, generate apoptosis signals, and induce cell death. The bioenergetic crisis may also be further exacerbated by reactive species damage to glycolytic and glutathione-mediated 
. Mitochondrial damage occurs in heart, liver, lung, kidney and nervous system diseases. For example, in Parkinson's disease, mitochondrial complex I activity is decreased, and mitochondrial DNA mutations accumulate. This damage, if not controlled, may be detrimental to cell survival. To deal with accumulated protein aggregates, oxidized lipid and associated proteins and damaged mitochondria, autophagic activities are required. Both enhanced and inhibited autophagy may be involved in tumorigenesis to accumulate damage and to enhance cell survival in the presence of genomic mutations, genotoxic agents, and under hypoxic conditions. Decreased autophagy is also detrimental to homeostasis of post-mitotic tissues such as occurs in neurodegenerative diseases, liver steatosis, cardiovascular and pulmonary diseases. Understanding the mechanisms and regulation of autophagy and mitophagy in disease pathogenesis may aid in the development of new strategies for treatment of proliferative and degenerative diseases.
antioxidant pathways. Because healthy mitochondrial function is essential for cell survival, selective removal of a subset of dysfunctional mitochondria is a highly regulated process and requires coordinated functions of mitochondrial and cytosolic proteins (Fig. 4) . This is controlled by a complex array of proteins which are constantly being revised and enhanced. For example, recent studies demonstrated that PINK1 is stabilized in the mitochondria in response to lowered membrane potential, recruits Parkin, which can ubiquitinate Mfn1 and 2, VDAC, TOMs, Fis1 and MIRO, and induce mitophagy [45] . Controlled mitophagy may coordinate with mitochondrial biogenesis to sustain cell survival and function [46] . Pharmacological activators and inhibitors, such as rapamycin, 3-methyladenine (3-MA) and chloroquine have aided research into autophagy regulation and consequence of altered autophagy and mitophagy regulation in health and diseases. Derivatives or additional compounds identified through high throughput screening may provide new, safe and effective compounds that target to autophagy and mitophagy pathway as treatment of cancer, neurodegenerative diseases, and diseases in the liver, heart, lung, kidney and b cells [47] . (9) bafilomycin and chloroquine that alter vacuolar and lysosomal pH, prevent autophagosomal-lysosomal fusion; or by E64 and pepstatin A that inhibit lysosomal protease activities. Inhibition of autophagy usually leads to enhanced cell death but in some circumstances autophagy can contribute to cytotoxicity. Identification and testing compounds that modulate autophagy and mitophagy is needed for treatment of a variety of diseases in which oxidative protein modification accumulates in the cell.
